Athersys Inc (ATHXQ)

[north40000]

Amarin's Vascepa may surprise. Its Reduce-It 8000+ patient clinical trial, Phase 3, is nearing completion with various CVDs as primary and secondary indications...stroke may be one of them. My off-label prescription for Vascepa costs me, co-pay, $9/month. Been prescribed since 4/1/2013. Also invested in ATHX

http://tinyurl.com/jpkouup
http://tinyurl.com/zyduacf
http://tinyurl.com/y84lurnu
http://tinyurl.com/lvdceaq

http://tinyurl.com/l562hk8
http://tinyurl.com/jnx6w6p";